BOSTON--(BUSINESS WIRE)--Fortis Life Sciences, LLC (“Fortis”) has acquired Toronto-based International Point of Care, Inc. (“IPOC”). IPOC develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. IPOC’s recently expanded 36,000 sq. ft. facility is Fortis’ third GMP and ISO 13485 compliant manufacturing site in North America.
“Diagnostics and life sciences companies want a partner that can custom-design and validate reagents for their applications; control quality and cost with vertically integrated in-house manufacturing; and help them get their products to market faster,” said Fred Pettijohn, Chief Business Officer of Fortis. “IPOC perfectly complements our existing capabilities, and we are pleased to introduce our expanded solution to the market.”
“We are excited to join Fortis and offer our customers a complete suite of high-quality materials and services,” said David Ray, CEO of IPOC. “Our combined expertise fully supports the diagnostic industry’s advances in ultra-high-sensitivity, point-of-care, and multiplexing applications, as well as in novel technologies such as quantitative lateral flow, isothermal amplification, and CRISPR-based diagnostics.”
About International Point of Care, Inc.
IPOC is based in Toronto, Ontario and specializes in developing and manufacturing diagnostic components. IPOC serves many of the leading global diagnostic companies enabling the commercialization of new immunodiagnostic and molecular diagnostic technologies. All IPOC’s development and manufacturing work is completed at its 36,000 sq. ft. GMP and ISO 13485:2016 facility in Toronto. To learn more about IPOC, please visit www.ipocdx.com.
About Fortis Life Sciences, LLC
Fortis partners with diagnostics and life sciences companies to custom-design, validate, and manufacture proprietary solutions to solve their most difficult development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America. To learn more about Fortis, please visit www.fortislife.com.
